Open Access<p>PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases</p>
Author(s) -
Chengtao Sun,
Fei Zhou,
Xuefei Li,
Chao Zhao,
Wei Li,
Jiayu Li,
Anwen Xiong,
Jia Yu,
Guanghui Gao,
Qi Wang,
Fengying Wu,
Caicun Zhou
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s286600
Subject(s) - medicine , lung cancer , chemotherapy , oncology , cancer , gastroenterology
Immune checkpoint inhibitor (ICI) monotherapy has limited efficacy in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). With the wide use of ICI-based combinations, the efficacy of different ICI combination strategies in patients with NSCLC and BMs needs to be further elucidated.